(Update1) Senator Hatch proposes amendment to Hatch-Waxman to prevent gaming of drug patent system with IPRs

Senator Orrin Hatch (R-UT), the chairman of the Senate Republican High-Tech Task Force and co-author of the Hatch-Waxman Act, filed an amendment in the Senate Judiciary Committee to restore the careful balance the Hatch-Waxman Act struck to incentivize generic drug development. The amendment, dubbed the Hatch-Waxman Integrity Act of 2018, would prevent generic drug companies [...]